Additionally, the role of SGLT2i in favorable cardiac remodeling in patients with high UACR is supported by the CREDENCE (Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation) trial, which found that treatment with the SGLT2i canagliflozin decreased NT-proBNP by 15% after 1 year in patients with T2DM and CKD with significant albuminuria, suggesting favorable cardiac remodeling mediated by dapagliflozin in the setting of kidney injury.22 This evidence concerns the gene NPPB and Nephropathy.